The Lurie Center at Massachusetts General Hospital
Introduction Schistosomiasis is recognized as the second most prevalent among the group of NTDs in sub-Saharan Africa, following hookworm infection ( Schistosoma , that results in chronic and acute disease ( Schistosoma are Schistosoma mansoni , Schistosoma haematobium , Schistosoma japonicum , Schistosoma intercalatum , and Schistosoma mekongi ( Schistosomiasis affects the worlds poorest countries where there is no safe water, basic sanitation and hygiene education ( The parasitizing of this infectious disease results in fever, malaise, abdominal pain, and skin rashes in an acute state, while intestinal, liver, urinary tract and lung diseases are the result of chronic infection
However, most experts agree that this is well below the physiological needs of most individuals
doi: 10.1161/STROKEAHA.114.004889 249 NabaviSFDeanOMTurnerASuredaADagliaMNabaviSM
LEVOCARNITINA - Solucin inyectable Sustancia(s): Levocarnitina Presentaciones: 1 Caja, 5 Ampolleta(s), 5 ml, 1 Gramos 1 Caja, 25 Ampolleta(s), 5 ml, 1 Gramos 1 Caja, 50 Ampolleta(s), 5 ml, 1 Gramos FORMA FARMACUTICA Y FORMULACIN: Cada AMPOLLETA contiene: Levocarnitina 1 g Vehculo 5 ml INDICACIONES TERAPUTICAS: Levocarnitina est indicada para las patologas con deficiencia de la misma de origen primario: Dao gentico de la biosntesis normal o la utilizacin de la levocarnitina proveniente de la dieta
)
